International Neuroblastoma Risk Group Staging System - pre-treatment, imaging-based.
The Neuroblastoma — INRGSS Stage is a oncology scoring tool used in paediatric practice. International Neuroblastoma Risk Group Staging System - pre-treatment, imaging-based. It scores 1 criteria and interprets the total across 4 bands, so the number always arrives with the severity it implies rather than on its own. In PediAid each criterion is shown as a labelled option with the weight it carries, so the total can be checked rather than taken on trust.
1. They are Extent of disease on imaging.
The total is interpreted as: 1 stage or more - Stage L1: l1 - localised without IDRFs. Surgery alone is often curative in low-risk biology; 2 stage or more - Stage L2: l2 - locoregional with IDRFs; upfront complete resection is hazardous. Neoadjuvant chemotherapy usually precedes surgery; 3 stage or more - Stage M: m - metastatic disease. High-risk therapy: induction chemotherapy, surgery, high-dose therapy with stem-cell rescue, radiotherapy, immunotherapy and retinoic acid; 4 stage or more - Stage MS: mS - special metastatic pattern in infants; frequently has an excellent outcome and can spontaneously regress, but assess MYCN and symptomatic hepatomegaly.
No. It is a structured way to record and communicate severity. A clinician concerned about a child should act on that concern regardless of the total.
Risk group also depends on age, MYCN amplification, histology, ploidy and 11q aberration.
Yes. Score definitions are bundled with the PediAid app, so the score computes without a connection.